Literature DB >> 22863010

Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.

Qiang Wen1, Benjamin Goldenson, Serena J Silver, Monica Schenone, Vlado Dancik, Zan Huang, Ling-Zhi Wang, Timothy A Lewis, W Frank An, Xiaoyu Li, Mark-Anthony Bray, Clarisse Thiollier, Lauren Diebold, Laure Gilles, Martha S Vokes, Christopher B Moore, Meghan Bliss-Moreau, Lynn Verplank, Nicola J Tolliday, Rama Mishra, Sasidhar Vemula, Jianjian Shi, Lei Wei, Reuben Kapur, Cécile K Lopez, Bastien Gerby, Paola Ballerini, Francoise Pflumio, D Gary Gilliland, Liat Goldberg, Yehudit Birger, Shai Izraeli, Alan S Gamis, Franklin O Smith, William G Woods, Jeffrey Taub, Christina A Scherer, James E Bradner, Boon-Cher Goh, Thomas Mercher, Anne E Carpenter, Robert J Gould, Paul A Clemons, Steven A Carr, David E Root, Stuart L Schreiber, Andrew M Stern, John D Crispino.   

Abstract

The mechanism by which cells decide to skip mitosis to become polyploid is largely undefined. Here we used a high-content image-based screen to identify small-molecule probes that induce polyploidization of megakaryocytic leukemia cells and serve as perturbagens to help understand this process. Our study implicates five networks of kinases that regulate the switch to polyploidy. Moreover, we find that dimethylfasudil (diMF, H-1152P) selectively increased polyploidization, mature cell-surface marker expression, and apoptosis of malignant megakaryocytes. An integrated target identification approach employing proteomic and shRNA screening revealed that a major target of diMF is Aurora kinase A (AURKA). We further find that MLN8237 (Alisertib), a selective inhibitor of AURKA, induced polyploidization and expression of mature megakaryocyte markers in acute megakaryocytic leukemia (AMKL) blasts and displayed potent anti-AMKL activity in vivo. Our findings provide a rationale to support clinical trials of MLN8237 and other inducers of polyploidization and differentiation in AMKL.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863010      PMCID: PMC3613864          DOI: 10.1016/j.cell.2012.06.032

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  41 in total

1.  Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia.

Authors:  Z Ma; S W Morris; V Valentine; M Li; J A Herbrick; X Cui; D Bouman; Y Li; P K Mehta; D Nizetic; Y Kaneko; G C Chan; L C Chan; J Squire; S W Scherer; J K Hitzler
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

2.  Identifying the proteins to which small-molecule probes and drugs bind in cells.

Authors:  Shao-En Ong; Monica Schenone; Adam A Margolin; Xiaoyu Li; Kathy Do; Mary K Doud; D R Mani; Letian Kuai; Xiang Wang; John L Wood; Nicola J Tolliday; Angela N Koehler; Lisa A Marcaurelle; Todd R Golub; Robert J Gould; Stuart L Schreiber; Steven A Carr
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

3.  A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Authors:  Güllü Görgün; Elisabetta Calabrese; Teru Hideshima; Jeffrey Ecsedy; Giulia Perrone; Mala Mani; Hiroshi Ikeda; Giada Bianchi; Yiguo Hu; Diana Cirstea; Loredana Santo; Yu-Tzu Tai; Sabikun Nahar; Mei Zheng; Madhavi Bandi; Ruben D Carrasco; Noopur Raje; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-09       Impact factor: 22.113

4.  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Authors:  Andrew A Mortlock; Kevin M Foote; Nicola M Heron; Frédéric H Jung; Georges Pasquet; Jean-Jacques M Lohmann; Nicolas Warin; Fabrice Renaud; Chris De Savi; Nicola J Roberts; Trevor Johnson; Cyril B Dousson; George B Hill; David Perkins; Glenn Hatter; Robert W Wilkinson; Stephen R Wedge; Simon P Heaton; Rajesh Odedra; Nicholas J Keen; Claire Crafter; Elaine Brown; Katherine Thompson; Stephen Brightwell; Liz Khatri; Madeleine C Brady; Sarah Kearney; David McKillop; Steve Rhead; Tony Parry; Stephen Green
Journal:  J Med Chem       Date:  2007-03-21       Impact factor: 7.446

5.  Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.

Authors:  Raghuveer Singh Mali; Baskar Ramdas; Peilin Ma; Jianjian Shi; Veerendra Munugalavadla; Emily Sims; Lei Wei; Sasidhar Vemula; Sarah C Nabinger; Charles B Goodwin; Rebecca J Chan; Fabiola Traina; Valeria Visconte; Ramon V Tiu; Timothy A Lewis; Andrew M Stern; Qiang Wen; John D Crispino; H Scott Boswell; Reuben Kapur
Journal:  Cancer Cell       Date:  2011-09-13       Impact factor: 31.743

6.  Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia.

Authors:  T Mercher; M B Coniat; R Monni; M Mauchauffe; F Nguyen Khac; L Gressin; F Mugneret; T Leblanc; N Dastugue; R Berger; O A Bernard
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

7.  AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Authors:  Robert W Wilkinson; Rajesh Odedra; Simon P Heaton; Stephen R Wedge; Nicholas J Keen; Claire Crafter; John R Foster; Madeleine C Brady; Alison Bigley; Elaine Brown; Kate F Byth; Nigel C Barrass; Kirsten E Mundt; Kevin M Foote; Nicola M Heron; Frederic H Jung; Andrew A Mortlock; F Thomas Boyle; Stephen Green
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

8.  Survivin is not required for the endomitotic cell cycle of megakaryocytes.

Authors:  Qiang Wen; Cindy Leung; Zan Huang; Sara Small; Alagarsamy Lakku Reddi; Jonathan D Licht; John D Crispino
Journal:  Blood       Date:  2009-04-01       Impact factor: 22.113

9.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

10.  Reactome: a knowledge base of biologic pathways and processes.

Authors:  Imre Vastrik; Peter D'Eustachio; Esther Schmidt; Geeta Joshi-Tope; Gopal Gopinath; David Croft; Bernard de Bono; Marc Gillespie; Bijay Jassal; Suzanna Lewis; Lisa Matthews; Guanming Wu; Ewan Birney; Lincoln Stein
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  66 in total

Review 1.  Kinase signaling and targeted therapy for primary myelofibrosis.

Authors:  Qiong Yang; John D Crispino; Qiang Jeremy Wen
Journal:  Exp Hematol       Date:  2016-12-30       Impact factor: 3.084

2.  The Hippo-p53 pathway in megakaryopoiesis.

Authors:  Praveen K Suraneni; John D Crispino
Journal:  Haematologica       Date:  2016-12       Impact factor: 9.941

Review 3.  Prognosis and management of acute myeloid leukemia in patients with Down syndrome.

Authors:  J Timothy Caldwell; Yubin Ge; Jeffrey W Taub
Journal:  Expert Rev Hematol       Date:  2014-09-18       Impact factor: 2.929

4.  Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.

Authors:  Marc Payton; Hung-Kam Cheung; Maria Stefania S Ninniri; Christian Marinaccio; William C Wayne; Kelly Hanestad; John D Crispino; Gloria Juan; Angela Coxon
Journal:  Mol Cancer Ther       Date:  2018-09-28       Impact factor: 6.261

5.  Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization.

Authors:  Rachelle E Kosoff; Joseph E Aslan; John C Kostyak; Essel Dulaimi; Hoi Yee Chow; Tatiana Y Prudnikova; Maria Radu; Satya P Kunapuli; Owen J T McCarty; Jonathan Chernoff
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

Review 6.  Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers.

Authors:  Anton M Jetten
Journal:  Trends Cancer       Date:  2019-08-20

7.  Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?

Authors:  Richard T Piszczatowski; Ulrich Steidl
Journal:  Clin Cancer Res       Date:  2019-06-13       Impact factor: 12.531

8.  Digital Image Analysis of Cells and Computational Tools for the Study of Mechanism of RSV Entry to Human Bronchial Epithelium.

Authors:  Margarita Gamarra; Eduardo Zurek
Journal:  Sist Tecnol Inf (2017)       Date:  2017-07-13

9.  Tetrandrine antagonizes acute megakaryoblastic leukaemia growth by forcing autophagy-mediated differentiation.

Authors:  Ting Liu; Zhenxing Zhang; Chunjie Yu; Chang Zeng; Xiaoqing Xu; Guixian Wu; Zan Huang; Wenhua Li
Journal:  Br J Pharmacol       Date:  2017-11-02       Impact factor: 8.739

10.  Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.

Authors:  Hiroto Inaba; Yinmei Zhou; Oussama Abla; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Eveline de Bont; Tai-Tsung Chang; Ursula Creutzig; Michael Dworzak; Sarah Elitzur; Alcira Fynn; Erik Forestier; Henrik Hasle; Der-Cherng Liang; Vincent Lee; Franco Locatelli; Riccardo Masetti; Barbara De Moerloose; Dirk Reinhardt; Laura Rodriguez; Nadine Van Roy; Shuhong Shen; Takashi Taga; Daisuke Tomizawa; Allen E J Yeoh; Martin Zimmermann; Susana C Raimondi
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.